Review



monoclonal mouse antihuman c5b 9  (Quidel)


Bioz Manufacturer Symbol Quidel manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Quidel monoclonal mouse antihuman c5b 9
    Monoclonal Mouse Antihuman C5b 9, supplied by Quidel, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse antihuman c5b 9/product/Quidel
    Average 86 stars, based on 1 article reviews
    monoclonal mouse antihuman c5b 9 - by Bioz Stars, 2025-07
    86/100 stars

    Images



    Similar Products

    86
    Quidel monoclonal mouse antihuman c5b 9
    Monoclonal Mouse Antihuman C5b 9, supplied by Quidel, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse antihuman c5b 9/product/Quidel
    Average 86 stars, based on 1 article reviews
    monoclonal mouse antihuman c5b 9 - by Bioz Stars, 2025-07
    86/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology monoclonal mouse antihuman c5b 9
    Complement activation on Neisseria meningitidis bypasses the amplification loop in post‐vaccination serum. Neisseria meningitidis was incubated with 10% FD‐deficient patient serum before (▲) and after (●) MenB‐4C vaccination. (a, b) show C3 and <t>C5b‐9</t> binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti‐C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b‐9 deposition in all circumstances. (c) Bacterial survival upon serum incubation as determined by CFU, demonstrating that bacterially killing was increased by addition of FD in the prevaccination serum, but not the postvaccination serum. When anti‐C1q was added, bacterial survival was around 100%, indicating that CP activation was required for bacterial killing. (d) Complement‐mediated E. coli killing was inhibited by addition of anti‐C1q alone to a similar extent as addition of anti‐C1q, anti‐FB and anti‐FD combined. Anti‐FB and anti‐FD alone were unable to prevent complement‐mediated bacterial killing. (a–c) Mean and individual data points from four independent experiments, (d) mean + SD from n = 3 independent experiments. Statistical significance in a–c was tested using the paired t ‐test, * P < 0.05, ** P < 0.01.
    Monoclonal Mouse Antihuman C5b 9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse antihuman c5b 9/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    monoclonal mouse antihuman c5b 9 - by Bioz Stars, 2025-07
    96/100 stars
      Buy from Supplier

    86
    Danaher Inc mouse monoclonal antihuman c5b 9 antibody
    Complement activation on Neisseria meningitidis bypasses the amplification loop in post‐vaccination serum. Neisseria meningitidis was incubated with 10% FD‐deficient patient serum before (▲) and after (●) MenB‐4C vaccination. (a, b) show C3 and <t>C5b‐9</t> binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti‐C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b‐9 deposition in all circumstances. (c) Bacterial survival upon serum incubation as determined by CFU, demonstrating that bacterially killing was increased by addition of FD in the prevaccination serum, but not the postvaccination serum. When anti‐C1q was added, bacterial survival was around 100%, indicating that CP activation was required for bacterial killing. (d) Complement‐mediated E. coli killing was inhibited by addition of anti‐C1q alone to a similar extent as addition of anti‐C1q, anti‐FB and anti‐FD combined. Anti‐FB and anti‐FD alone were unable to prevent complement‐mediated bacterial killing. (a–c) Mean and individual data points from four independent experiments, (d) mean + SD from n = 3 independent experiments. Statistical significance in a–c was tested using the paired t ‐test, * P < 0.05, ** P < 0.01.
    Mouse Monoclonal Antihuman C5b 9 Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal antihuman c5b 9 antibody/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    mouse monoclonal antihuman c5b 9 antibody - by Bioz Stars, 2025-07
    86/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology mouse monoclonal antihuman c5b 9 antibody
    Complement activation on Neisseria meningitidis bypasses the amplification loop in post‐vaccination serum. Neisseria meningitidis was incubated with 10% FD‐deficient patient serum before (▲) and after (●) MenB‐4C vaccination. (a, b) show C3 and <t>C5b‐9</t> binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti‐C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b‐9 deposition in all circumstances. (c) Bacterial survival upon serum incubation as determined by CFU, demonstrating that bacterially killing was increased by addition of FD in the prevaccination serum, but not the postvaccination serum. When anti‐C1q was added, bacterial survival was around 100%, indicating that CP activation was required for bacterial killing. (d) Complement‐mediated E. coli killing was inhibited by addition of anti‐C1q alone to a similar extent as addition of anti‐C1q, anti‐FB and anti‐FD combined. Anti‐FB and anti‐FD alone were unable to prevent complement‐mediated bacterial killing. (a–c) Mean and individual data points from four independent experiments, (d) mean + SD from n = 3 independent experiments. Statistical significance in a–c was tested using the paired t ‐test, * P < 0.05, ** P < 0.01.
    Mouse Monoclonal Antihuman C5b 9 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal antihuman c5b 9 antibody/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    mouse monoclonal antihuman c5b 9 antibody - by Bioz Stars, 2025-07
    96/100 stars
      Buy from Supplier

    86
    Abcam mouse antihuman baboon c5b 9 mab
    Complement activation on Neisseria meningitidis bypasses the amplification loop in post‐vaccination serum. Neisseria meningitidis was incubated with 10% FD‐deficient patient serum before (▲) and after (●) MenB‐4C vaccination. (a, b) show C3 and <t>C5b‐9</t> binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti‐C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b‐9 deposition in all circumstances. (c) Bacterial survival upon serum incubation as determined by CFU, demonstrating that bacterially killing was increased by addition of FD in the prevaccination serum, but not the postvaccination serum. When anti‐C1q was added, bacterial survival was around 100%, indicating that CP activation was required for bacterial killing. (d) Complement‐mediated E. coli killing was inhibited by addition of anti‐C1q alone to a similar extent as addition of anti‐C1q, anti‐FB and anti‐FD combined. Anti‐FB and anti‐FD alone were unable to prevent complement‐mediated bacterial killing. (a–c) Mean and individual data points from four independent experiments, (d) mean + SD from n = 3 independent experiments. Statistical significance in a–c was tested using the paired t ‐test, * P < 0.05, ** P < 0.01.
    Mouse Antihuman Baboon C5b 9 Mab, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse antihuman baboon c5b 9 mab/product/Abcam
    Average 86 stars, based on 1 article reviews
    mouse antihuman baboon c5b 9 mab - by Bioz Stars, 2025-07
    86/100 stars
      Buy from Supplier

    86
    Agilent technologies monoclonal mouse antihuman c5b 9 igg
    Complement activation on Neisseria meningitidis bypasses the amplification loop in post‐vaccination serum. Neisseria meningitidis was incubated with 10% FD‐deficient patient serum before (▲) and after (●) MenB‐4C vaccination. (a, b) show C3 and <t>C5b‐9</t> binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti‐C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b‐9 deposition in all circumstances. (c) Bacterial survival upon serum incubation as determined by CFU, demonstrating that bacterially killing was increased by addition of FD in the prevaccination serum, but not the postvaccination serum. When anti‐C1q was added, bacterial survival was around 100%, indicating that CP activation was required for bacterial killing. (d) Complement‐mediated E. coli killing was inhibited by addition of anti‐C1q alone to a similar extent as addition of anti‐C1q, anti‐FB and anti‐FD combined. Anti‐FB and anti‐FD alone were unable to prevent complement‐mediated bacterial killing. (a–c) Mean and individual data points from four independent experiments, (d) mean + SD from n = 3 independent experiments. Statistical significance in a–c was tested using the paired t ‐test, * P < 0.05, ** P < 0.01.
    Monoclonal Mouse Antihuman C5b 9 Igg, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse antihuman c5b 9 igg/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    monoclonal mouse antihuman c5b 9 igg - by Bioz Stars, 2025-07
    86/100 stars
      Buy from Supplier

    86
    Agilent technologies monoclonal mouse antihuman c5b 9
    Complement activation on Neisseria meningitidis bypasses the amplification loop in post‐vaccination serum. Neisseria meningitidis was incubated with 10% FD‐deficient patient serum before (▲) and after (●) MenB‐4C vaccination. (a, b) show C3 and <t>C5b‐9</t> binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti‐C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b‐9 deposition in all circumstances. (c) Bacterial survival upon serum incubation as determined by CFU, demonstrating that bacterially killing was increased by addition of FD in the prevaccination serum, but not the postvaccination serum. When anti‐C1q was added, bacterial survival was around 100%, indicating that CP activation was required for bacterial killing. (d) Complement‐mediated E. coli killing was inhibited by addition of anti‐C1q alone to a similar extent as addition of anti‐C1q, anti‐FB and anti‐FD combined. Anti‐FB and anti‐FD alone were unable to prevent complement‐mediated bacterial killing. (a–c) Mean and individual data points from four independent experiments, (d) mean + SD from n = 3 independent experiments. Statistical significance in a–c was tested using the paired t ‐test, * P < 0.05, ** P < 0.01.
    Monoclonal Mouse Antihuman C5b 9, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse antihuman c5b 9/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    monoclonal mouse antihuman c5b 9 - by Bioz Stars, 2025-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Complement activation on Neisseria meningitidis bypasses the amplification loop in post‐vaccination serum. Neisseria meningitidis was incubated with 10% FD‐deficient patient serum before (▲) and after (●) MenB‐4C vaccination. (a, b) show C3 and C5b‐9 binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti‐C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b‐9 deposition in all circumstances. (c) Bacterial survival upon serum incubation as determined by CFU, demonstrating that bacterially killing was increased by addition of FD in the prevaccination serum, but not the postvaccination serum. When anti‐C1q was added, bacterial survival was around 100%, indicating that CP activation was required for bacterial killing. (d) Complement‐mediated E. coli killing was inhibited by addition of anti‐C1q alone to a similar extent as addition of anti‐C1q, anti‐FB and anti‐FD combined. Anti‐FB and anti‐FD alone were unable to prevent complement‐mediated bacterial killing. (a–c) Mean and individual data points from four independent experiments, (d) mean + SD from n = 3 independent experiments. Statistical significance in a–c was tested using the paired t ‐test, * P < 0.05, ** P < 0.01.

    Journal: Clinical & Translational Immunology

    Article Title: The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation

    doi: 10.1002/cti2.1436

    Figure Lengend Snippet: Complement activation on Neisseria meningitidis bypasses the amplification loop in post‐vaccination serum. Neisseria meningitidis was incubated with 10% FD‐deficient patient serum before (▲) and after (●) MenB‐4C vaccination. (a, b) show C3 and C5b‐9 binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti‐C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b‐9 deposition in all circumstances. (c) Bacterial survival upon serum incubation as determined by CFU, demonstrating that bacterially killing was increased by addition of FD in the prevaccination serum, but not the postvaccination serum. When anti‐C1q was added, bacterial survival was around 100%, indicating that CP activation was required for bacterial killing. (d) Complement‐mediated E. coli killing was inhibited by addition of anti‐C1q alone to a similar extent as addition of anti‐C1q, anti‐FB and anti‐FD combined. Anti‐FB and anti‐FD alone were unable to prevent complement‐mediated bacterial killing. (a–c) Mean and individual data points from four independent experiments, (d) mean + SD from n = 3 independent experiments. Statistical significance in a–c was tested using the paired t ‐test, * P < 0.05, ** P < 0.01.

    Article Snippet: Surface‐bound complement C3 and complement complex C5b‐9 were detected with 1:500‐diluted FITC‐labelled polyclonal goat anti‐human C3 (MP biomedicals) and 1:100‐diluted monoclonal mouse antihuman C5b‐9 (Clone aE11, Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by 1:500‐diluted Alexa647‐labelled donkey antimouse IgG (Invitrogen).

    Techniques: Activation Assay, Amplification, Incubation, Binding Assay, Flow Cytometry, Inhibition